Harvard Bioscience, Inc. (FRA:HBI)

Germany flag Germany · Delayed Price · Currency is EUR
0.610
+0.005 (0.83%)
At close: Dec 4, 2025
-70.10%
Market Cap 27.63M
Revenue (ttm) 74.47M
Net Income (ttm) -45.88M
Shares Out n/a
EPS (ttm) -1.04
PE Ratio n/a
Forward PE 8.24
Dividend n/a
Ex-Dividend Date n/a
Volume n/a
Average Volume 2,132
Open 0.610
Previous Close 0.605
Day's Range 0.610 - 0.610
52-Week Range 0.214 - 2.180
Beta n/a
RSI 56.21
Earnings Date Mar 6, 2026

About Harvard Bioscience

Harvard Bioscience, Inc. develops, manufactures, and sells technologies, products, and services for life science applications in the United States, Germany, and internationally. The company offers cellular and molecular technology products, such as syringe and peristaltic infusion pump products; electroporation and electrofusion instruments, amino acid analyzers, spectrophotometers, and other equipment for molecular level testing and research; and precision scientific measuring instrumentation and equipment, including data acquisition systems f... [Read more]

Industry Laboratory Analytical Instruments
Founded 1901
Employees 355
Stock Exchange Frankfurt Stock Exchange
Ticker Symbol HBI
Full Company Profile

Financial Performance

In 2024, Harvard Bioscience's revenue was $94.14 million, a decrease of -16.14% compared to the previous year's $112.25 million. Losses were -$12.41 million, 263.3% more than in 2023.

Financial numbers in USD Financial Statements

News

There is no news available yet.